Demonstrates improved outcomes in Merkel cell carcinoma using Avelumab immunotherapy, suggesting effective treatment for non-surgical patients.
Merkel cell carcinoma is an aggressive form of cancer with poor prognosis, particularly for individuals deemed unsuitable for surgical resection. With new immunotherapy agents being used alone or as an adjuvant treatment, improving long term outcomes are being seen, even for those deemed to be treated with palliative intent.
No takes yet. Share an insight, caveat, or question.
Byrne et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: